Abstract
The use of drug eluting stents (DES) majorly reduced in-stent restenosis though preventing not only recoil of the vessel wall and late negative remodelling, but also significantly inhibiting neo-intimal hyperplasia formation. However, concerns about in-stent thrombosis, and the dependency on prolonged dual antiplatelet therapy, and continued restenosis in complex lesion subsets, led to a search for alternative treatment devices that will tackle restenosis rates without the drawbacks associated with DES.2-5 1. University Medical Center Utrecht, department of Interventional Cardiology
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
